Roles of S100 family members in drug resistance in tumors: Status and prospects - 30/05/20
![](/templates/common/images/mail.png)
![](/templates/common/images/mail.png)
![](/templates/common/images/mail.png)
![](/templates/common/images/mail.png)
![](/templates/common/images/mail.png)
![](/templates/common/images/mail.png)
pages | 14 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | Development of multiple drug resistance in tumors is a multifactorial process. |
• | S100 proteins are closely involved in tumor drug resistance via multiple pathways. |
• | Targeting S100 proteins may promote or relieve drug resistance in tumors. |
Abstract |
Chemotherapy and targeted therapy can significantly improve survival rates in cancer, but multiple drug resistance (MDR) limits the efficacy of these approaches. Understanding the molecular mechanisms underlying MDR is crucial for improving drug efficacy and clinical outcomes of patients with cancer. S100 proteins belong to a family of calcium-binding proteins and have various functions in tumor development. Increasing evidence demonstrates that the dysregulation of various S100 proteins contributes to the development of drug resistance in tumors, providing a basis for the development of predictive and prognostic biomarkers in cancer. Therefore, a combination of biological inhibitors or sensitizers of dysregulated S100 proteins could enhance therapeutic responses. In this review, we provide a detailed overview of the mechanisms by which S100 family members influence resistance of tumors to cancer treatment, with a focus on the development of effective strategies for overcoming MDR.
Le texte complet de cet article est disponible en PDF.Abbreviations : 5-FU, ALL, AML, ANXA2, BAX, BECN1, circMTO1, CML, CRC, CSC, CXCL, DDP, EGFR, EMT, ERK, GST, IFN, IHC, IL, LRP, MAPK, MDR, MDSC, MLL, MMP, MRP-1, mTOR, NF-κB, NSCLC, PEP005, PI3K/AKT, RAGE, RAR, TAM, TME, TNF, TSN
Keywords : S100 protein, Drug resistance, Tumor, Chemotherapy, Biomarker
Plan
Vol 127
Article 110156- juillet 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?